Michael G. Kauffman
2017
In 2017, Michael G. Kauffman earned a total compensation of $2.7M as Chief Executive Officer at Karyopharm Therapeutics, a 73% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $251,503 |
---|---|
Option Awards | $1,857,650 |
Salary | $530,500 |
Other | $11,460 |
Total | $2,651,113 |
Kauffman received $1.9M in option awards, accounting for 70% of the total pay in 2017.
Kauffman also received $251.5K in non-equity incentive plan, $530.5K in salary and $11.5K in other compensation.
Rankings
In 2017, Michael G. Kauffman's compensation ranked 4,190th out of 14,666 executives tracked by ExecPay. In other words, Kauffman earned more than 71.4% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 4,190 | 71st |
Manufacturing | 1,467 | 75th |
Chemicals And Allied Products | 420 | 80th |
Drugs | 321 | 82nd |
Pharmaceutical Preparations | 255 | 81st |
Kauffman's colleagues
We found two more compensation records of executives who worked with Michael G. Kauffman at Karyopharm Therapeutics in 2017.
News
Karyopharm Therapeutics CEO Richard Paulson receives $8.4M in 2021
April 8, 2022
Karyopharm Therapeutics CEO Michael Kauffman's 2020 pay jumps 22% to $3.9M
April 7, 2021
Karyopharm Therapeutics CEO Michael Kauffman's 2019 pay jumps 42% to $3.2M
April 9, 2020
Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer Anand Varadan receives $2.3M in 2018
April 19, 2019